HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Siegel, J. A. Articles by Stabin, M. G. Search for Related Content PubMed PubMed Citation Articles by Siegel, J. A. Articles by Stabin, M. G.

Absorbed Fractions for Electrons and Beta Particles in Spheres of Various Sizes

Cooper Hospital, University Medical Center, Department of Radiation Oncology, Camden, New Jersey
Radiation Internal Dose Information Center, Medical Sciences Division, Oak Ridge Institute for Science and Education, Oak Ridge, Tennessee

Correspondence: For correspondence or reprints contact: Jeffry A. Siegel, PhD, Cooper Hospital, University Medical Center, Dept. of Radiation Oncology, 1 Cooper Plaza, Camden, NJ 08103.

ABSTRACT

The use of electron-emitting radionuclides in tumor imaging and therapy has presented some new challenges to conventional radiation dosimetry. The fraction of electron energy absorbed in most source regions has usually been assumed to be unity. In small structures such as localized tumors or isolated regions containing moderate to high energy electron emitters, however, this may not always be the case. Methods: Using an extension of Berger's scaled absorbed dose distributions for point sources to represent a spherical geometry, absorbed fractions of electron energy for sources uniformly distributed in spheres of various sizes have been calculated. Results: Beta particle and monoenergetic electron energies studied range from 0.025 to 4.0 MeV and sphere masses range from 0.01 to 1000 g. S values have also been calculated for ⁹⁰Y, ¹²³I and ¹³¹I based on the results of the absorbed fraction calculations. Conclusion: These calculated absorbed fractions are valuable in estimating electron energy loss from small spherical structures and may be useful in estimating the radiation dose to these small volumes.

Key Words: beta particles • electron-emitting radionuclides • radiation dosimetry • ¹²³I • ⁹⁰Y • ¹³¹I

This article has been cited by other articles:

				F. Buchegger, O. W. Press, A. B. Delaloye, and N. Ketterer Radiolabeled and Native Antibodies and the Prospect of Cure of Follicular Lymphoma Oncologist, June 1, 2008; 13(6): 657 - 667. [Abstract] [Full Text] [PDF]

				C. Champion, P. Zanotti-Fregonara, and E. Hindie CELLDOSE: A Monte Carlo Code to Assess Electron Dose Distribution S Values for 131I in Spheres of Various Sizes J. Nucl. Med., January 1, 2008; 49(1): 151 - 157. [Abstract] [Full Text] [PDF]

				G A Kaltsas, D Papadogias, P Makras, and A B Grossman Treatment of advanced neuroendocrine tumours with radiolabelled somatostatin analogues Endocr. Relat. Cancer, December 1, 2005; 12(4): 683 - 699. [Abstract] [Full Text] [PDF]

				G. L. DeNardo, E. Tobin, K. Chan, B. M. Bradt, and S. J. DeNardo Direct Antilymphoma Effects on Human Lymphoma Cells of Monotherapy and Combination Therapy with CD20 and HLA-DR Antibodies and 90Y-Labeled HLA-DR Antibodies Clin. Cancer Res., October 1, 2005; 11(19): 7075s - 7079s. [Abstract] [Full Text] [PDF]

				M. G. Stabin, R. B. Sparks, and E. Crowe OLINDA/EXM: The Second-Generation Personal Computer Software for Internal Dose Assessment in Nuclear Medicine J. Nucl. Med., June 1, 2005; 46(6): 1023 - 1027. [Abstract] [Full Text] [PDF]

				R. B. Michel, P. M. Andrews, M. E. Castillo, and M. J. Mattes In vitro cytotoxicity of carcinoma cells with 111In-labeled antibodies to HER-2 Mol. Cancer Ther., June 1, 2005; 4(6): 927 - 937. [Abstract] [Full Text] [PDF]

				S. Shen, A. Forero, A. F. LoBuglio, H. Breitz, M.B. Khazaeli, D. R. Fisher, W. Wang, and R. F. Meredith Patient-Specific Dosimetry of Pretargeted Radioimmunotherapy Using CC49 Fusion Protein in Patients with Gastrointestinal Malignancies J. Nucl. Med., April 1, 2005; 46(4): 642 - 651. [Abstract] [Full Text] [PDF]

				R. Stein, S. V. Govindan, M. Hayes, G. L. Griffiths, H. J. Hansen, I. D. Horak, and D. M. Goldenberg Advantage of a Residualizing Iodine Radiolabel in the Therapy of a Colon Cancer Xenograft Targeted with an Anticarcinoembryonic Antigen Monoclonal Antibody Clin. Cancer Res., April 1, 2005; 11(7): 2727 - 2734. [Abstract] [Full Text] [PDF]

				M. de Jong, W. A.P. Breeman, R. Valkema, B. F. Bernard, and E. P. Krenning Combination Radionuclide Therapy Using 177Lu- and 90Y-Labeled Somatostatin Analogs J. Nucl. Med., January 1, 2005; 46(1_suppl): 13S - 17S. [Abstract] [Full Text] [PDF]

				R. B. Michel, M. E. Castillo, P. M. Andrews, and M. J. Mattes In vitro Toxicity of A-431 Carcinoma Cells with Antibodies to Epidermal Growth Factor Receptor and Epithelial Glycoprotein-1 Conjugated to Radionuclides Emitting Low-Energy Electrons Clin. Cancer Res., September 1, 2004; 10(17): 5957 - 5966. [Abstract] [Full Text] [PDF]

				A. H. Brouwers, J. E.M. van Eerd, C. Frielink, E. Oosterwijk, W. J.G. Oyen, F. H.M. Corstens, and O. C. Boerman Optimization of Radioimmunotherapy of Renal Cell Carcinoma: Labeling of Monoclonal Antibody cG250 with 131I, 90Y, 177Lu, or 186Re J. Nucl. Med., February 1, 2004; 45(2): 327 - 337. [Abstract] [Full Text] [PDF]

				S. J. DeNardo, G. L. DeNardo, A. Yuan, C. M. Richman, R. T. O'Donnell, P. N. Lara, D. L. Kukis, A. Natarajan, K. R. Lamborn, F. Jacobs, et al. Enhanced Therapeutic Index of Radioimmunotherapy (RIT) in Prostate Cancer Patients: Comparison of Radiation Dosimetry for 1,4,7,10-Tetraazacyclododecane-N,N',N'',N'''-Tetraacetic Acid (DOTA)-Peptide versus 2IT-DOTA Monoclonal Antibody Linkage for RIT Clin. Cancer Res., September 1, 2003; 9(10): 3938S - 3944. [Abstract] [Full Text] [PDF]

				C. L. Hartmann Siantar, G. L. DeNardo, and S. J. DeNardo Impact of Nodal Regression on Radiation Dose for Lymphoma Patients After Radioimmunotherapy J. Nucl. Med., August 1, 2003; 44(8): 1322 - 1329. [Abstract] [Full Text] [PDF]

				K. Liepe, R. Hliscs, J. Kropp, R. Runge, F. F. Knapp Jr., and W.-G. Franke Dosimetry of 188Re-Hydroxyethylidene Diphosphonate in Human Prostate Cancer Skeletal Metastases J. Nucl. Med., June 1, 2003; 44(6): 953 - 960. [Abstract] [Full Text] [PDF]

				K. S. Kolbert, T. Watson, C. Matei, S. Xu, J. A. Koutcher, and G. Sgouros Murine S Factors for Liver, Spleen, and Kidney J. Nucl. Med., May 1, 2003; 44(5): 784 - 791. [Abstract] [Full Text] [PDF]

				R. Stein, S. V. Govindan, M. J. Mattes, S. Chen, L. Reed, G. Newsome, B. J. McBride, G. L. Griffiths, H. J. Hansen, and D. M. Goldenberg Improved Iodine Radiolabels for Monoclonal Antibody Therapy Cancer Res., January 1, 2003; 63(1): 111 - 118. [Abstract] [Full Text] [PDF]

				M. de Jong, W. A.P. Breeman, B. F. Bernard, W. H. Bakker, T. J. Visser, P. P.M. Kooij, A. van Gameren, and E. P. Krenning Tumor Response After [90Y-DOTA0,Tyr3]Octreotide Radionuclide Therapy in a Transplantable Rat Tumor Model Is Dependent on Tumor Size J. Nucl. Med., December 1, 2001; 42(12): 1841 - 1846. [Abstract] [Full Text] [PDF]

				R. Stein, S. V. Govindan, S. Chen, L. Reed, H. Richel, G. L. Griffiths, H. J. Hansen, and D. M. Goldenberg Radioimmunotherapy of a Human Lung Cancer Xenograft with Monoclonal Antibody RS7: Evaluation of 177Lu and Comparison of Its Efficacy with That of 90Y and Residualizing 131I J. Nucl. Med., June 1, 2001; 42(6): 967 - 974. [Abstract] [Full Text] [PDF]

				S. V. Govindan, D. M. Goldenberg, S. E. Elsamra, G. L. Griffiths, G. L. Ong, M. W. Brechbiel, J. Burton, G. Sgouros, and M. J. Mattes Radionuclides Linked to a CD74 Antibody as Therapeutic Agents for B-Cell Lymphoma: Comparison of Auger Electron Emitters with {beta}-Particle Emitters J. Nucl. Med., December 1, 2000; 41(12): 2089 - 2097. [Abstract] [Full Text] [PDF]